Background. The aim of this study was to assess the prognostic significance of the newly proposed 2015 World Health Organization (WHO) lung adenocarcinoma classification for patients undergoing resection for small (≤1 cm) lung adenocarcinoma. We also investigated whether lobectomy offers prognostic advantage over limited resection for this category of tumors. Methods. A retrospective study of resected pulmonary adenocarcinomas (n = 83) in sizes 1 cm or less was carried out in which comprehensive histologic subtyping was assessed according to the 2015 WHO classification on all consecutive patients who underwent lobectomy or limited resection between 1998 and 2012. Correlation between clinicopathologic parameters and the difference in recurrence between lobectomy and limited resection group was evaluated. Results. Our data show that the proposed 2015 WHO classification identifies histological subsets of small lung adenocarcinomas with significant differences in prognosis. No recurrence was noted for patients with adenocarcinoma in situ and minimally invasive adenocarcinoma. Invasive adenocarcinomas displayed high heterogeneity and the presence of micropapillary component of 5% or greater in adenocarcinomas was significantly related to lymph node involvement and recurrence (P < .001). Stage IA patients who underwent limited resection had a higher risk of recurrence than did those treated by lobectomy (P < .05). Conclusions. Application of the 2015 WHO classification identifies patients with adenocarcinoma in situ and minimally invasive adenocarcinoma had excellent prognosis. Micropapillary pattern was associated with high risk of lymph node metastasis and recurrence. Keywords small lung adenocarcinoma 1 cm or less in size, adenocarcinoma in situ, minimally invasive adenocarcinoma, micropapillary pattern, lobectomy, limited resection
Original Article
Lung cancer is the leading cause of cancer deaths worldwide. At present adenocarcinoma is the most common histologic subtype, accounting for almost half of all lung cancers. 1 With the widespread use of screening programs as well as advances in high-resolution computed tomography, small lung adenocarcinoma is more frequently detected in sizes 1 cm or less, which usually present in the periphery of the lung. 2 Currently, lobectomy is still the gold standard for resection of early-stage lung cancer, 3, 4 but some surgeons have suggested that peripheral small lung adenocarcinoma is treatable by limited resection (segmentectomy or wedge resection). 5, 6 However, there is controversy regarding the optimal surgical approach for these small lung adenocarcinomas.
Recently, an international multidisciplinary classification system for lung adenocarcinoma based on histologic architecture was sponsored by the World Health Organization (WHO) in 2015. 7 To date, very few studies have investigated the utility of the new classification for patients with small lung adenocarcinomas. Here, we studied a series of small lung adenocarcinomas (≤1 cm) and correlated the revised classification system with histopathologic features to identify features relevant to tumor recurrence and lymph 721649I JSXXX10.1177/1066896917721649International Journal of Surgical PathologyZhao et al research-article2017 1 The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, China node metastasis. We also evaluated limited resection versus lobectomy on the recurrence of these tumors.
Patients and Methods

Patients
We evaluated a retrospective series of resected, preoperatively untreated small adenocarcinomas of the lung in sizes 1 cm or less from the database of the First People's Hospital of Changzhou between 1998 and 2012. All the patients were confirmed to have no distant metastases by head and chest/abdominal computed tomography and radionuclide bone scanning before operation. Clinical information was obtained from detailed prospective clinical databases. Patients were staged according to the seventh edition of the American Joint Committee on Cancer TNM Staging Manual for lung cancers. 8 
Histological Evaluation
All resected specimens were fixed routinely in 10% formalin. Gross size was recorded as reported in the original pathology report. The entire tumors were submitted for microscopic evaluation. Each of the specimens was cut into 4-μm-thick sections. Sections of the tumor were stained by hematoxylin and eosin. Tumors were evaluated for histologic patterns by 2 pathologists using the 2015 WHO lung adenocarcinoma classification system (Table  1) . Comprehensive histologic evaluation of adenocarcinomas was performed in a semiquantitative style by recording the percentage of each histologic component in 5% increments, totaling 100% for a tumor. 9, 10 we classified tumors by their predominant morphologic percentage: (1) adenocarcinoma in situ ( Figure 1) ; minimally invasive adenocarcinoma (<5 mm) ( Figure 2) ; invasive adenocarcinomas (Figure 3) , which was further divided into acinar predominant ( Figure 3A ), papillary predominant ( Figure  3B ), micropapillary predominant ( Figure 3C ), solid predominant ( Figure 3D ), invasive mucinous adenocarcinoma (Figure 4) , and colloid predominant adenocarcinoma ( Figure 5 ).
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Invasion criteria were applied as follows: (1) loss of alveolar architecture with desmoplastic stroma; (2) gland shapes not conforming to preexisting architecture; and 3) papillary, micropapillary, or solid growth pattern. Tumor size was measured according to standard gross. Size of the invasive component was measured under the microscope on a single slide.
Recurrence Evaluation
All recurrences were confirmed by histologic examination after clinical or radiologic suspicion. Recurrences were classified according to the guideline of the Society of Thoracic Surgeons Workforce recommendations. 12 Local recurrence was defined by evidence of a tumor in the same lobe or at the surgical margin of the original tumor. Regional recurrence was defined by evidence of a tumor in a second homolateral lobe, in the homolateral hilar lymph nodes (N1), or in the homolateral mediastinal lymph nodes (N2). Distant recurrence was defined by evidence of a tumor in the contralateral lung, in the contralateral mediastinal or ipsilateral supraclavicular lymph nodes (N3), or elsewhere outside the hemithorax.
Statistical Analysis
Difference in recurrence between lobectomy and limited resection group was evaluated using the chi-square test. Correlation between clinicopathologic parameters was determined using the chi-square and Fisher exact tests. All statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 17.0 (SPSS, Chicago, IL). Significance was determined when probability (P) values were <.05 and all tests were 2-sided.
Results
Clinical Characteristics
The clinicopathologic characteristics are summarized in Table 2 . There were 53 women (64%) and 30 men (36%), with a mean age of 60 years (range, 38-79 years). In all, 54 tumors (65%) were located in right lung and 29 tumors (35%) were located in left lung. Forty-four available. There were 13 recurrences (n = 8 local; n = 2 regional; n = 3 distant) detected during the follow-up period. The analysis of recurrence and difference in recurrence between lobectomy and limited resection group is summarized in Table 3 .
Histologic Features
The distribution of histological subtypes according to the 2015 WHO lung adenocarcinoma classifications is summarized in Table 2 . According to the 2015 WHO classification, 5 cases of adenocarcinoma in situ and 11 cases of minimally invasive adenocarcinoma were nonmucinous. Among invasive adenocarcinomas, 57 cases of 67 (85%) showed at least 2 architectural patterns (minor heterogeneity). Histologic details are listed in Table 4 .
Correlations of Histology With Clinical Characteristics
Statistically, only the presence of a micropapillary pattern in adenocarcinoma was significantly related to lymph node involvement (P < .001) and recurrence (P < .001) ( Table 5 ).
Discussion
Recently, the WHO proposed a novel classification system for lung adenocarcinomas and this approach underscored important observations in the histology of adenocarcinoma from preinvasive to invasive adenocarcinoma. Meanwhile, recent data had shown that a benefit of screening computed tomography scan will increase the detection of smaller and possibly more curable tumors. 2 However, to date, very few studies have investigated the prognostic utility of the newly WHO classification for patients with small lung adenocarcinoma, especially those in sizes 1 cm or less. In the 2015 WHO classification, a distinction must be made between atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma, and variants of invasive adenocarcinoma. The former term bronchioloalveolar carcinoma (BAC), defined as lesions with in situ lepidic growth, is no longer included in the 2015 WHO classification, due to widespread confusion over its application to a broad range of tumors. For greater clarity, it also replaces the former "mixed" subtype with predominant histologic subtype characterization of resected specimens.
Our data show that the 2015 WHO classification identifies histological subsets of small lung adenocarcinomas in sizes 1 cm or less with significant differences in prognosis. In our cohort, there were 5 cases of adenocarcinoma in situ and 11 cases of minimally invasive adenocarcinoma. No recurrence was noted during our follow-up study period for patients with adenocarcinoma in situ and minimally invasive adenocarcinoma. Among patients with invasive adenocarcinomas, recurrence was 21% (13/62). According to our results, it would be expected that adenocarcinoma in situ and minimally invasive adenocarcinoma would have a more favorable prognosis than invasive carcinoma. In a previous study Noguchi et al 13 described patterns of nonmucinous BAC and these patients had 100% 5-year survival. Shimosato et al 14 also proposed that small peripheral adenocarcinomas could be cured surgically. Our data were in concordance with these results.
Even in sizes 1 cm or less, lung adenocarcinomas still showed high heterogeneity at histology. In our series, only 10 cases of small lung invasive adenocarcinomas showed single growth pattern, including acinar type (4 cases), papillary type (3 cases), micropapillary (1 case), mucinous (1 case), and colloid (1 case). The remaining 85% (57/67) of small lung invasive adenocarcinomas displayed from 2 to 4 different growth patterns (Table 4) . These predominantly invasive adenocarcinomas comprise the largest subset of tumors in our series. By using the method of comprehensive histological subtyping, 7, 9, 11, 15, 16 we were able to classify the tumors according to the predominant subtype. Warth et al 17 found a single pattern in only 7.4% surgically resected adenocarcinomas specimens, whereas the remaining 92.6% displayed from 2 to 4 different growth patterns. Dunnill and Gatter 18 also found that only 18 of 66 surgically resected lung cancers had a unique single cell-type differentiation. Our finding was similar to these reports.
We also found that micropapillary morphologic pattern as an independent risk factor for lymph node metastasis and recurrence in patients with small lung adenocarcinomas. In our cohort, micropapillary pattern leads to stage II in two cases and stage III in 3 cases. Moreover, we also found that patients with tumors with micropapillary component of 5% or greater are at a higher risk of recurrence than patients without micropapillary component. Now micropapillary histologic subtype is established as a factor of poor prognosis, and it was recognized as a major category of lung adenocarcinoma in the 2015 WHO classification. [19] [20] [21] [22] [23] [24] These previous reports and our study support the idea that patients with these tumors may be candidates for more radical lobectomy and adjuvant therapy.
In recent years, there have been attempts at evaluations of limited resection versus lobectomy in patients with early-stage small lung cancer. 25, 26 These studies support the conclusions that lobectomy would be the gold-standard anatomic resection. Whitson et al 27 also demonstrated that lobectomy had superior survival over segmental resections. In our study, among patients with stage Ia tumors, limited resection had higher risk of recurrence than did lobectomy (27% vs 3.7%; P < .05). Although some authors have suggested that limited resections are adequate treatment for early-stage disease, 28, 29 more and more recent reports showed that patients who underwent a limited resection had a higher recurrence and lower survival than did those treated by lobectomy. There are several limitations in our study. Our study is a noncontrolled, retrospective study that is reflective of the outcomes at one hospital. Other histologic subtypes were also evaluated, but their relationships with risk of recurrence were inconclusive and are not reported here. The sample size in our series is too small to make definitive recommendations on the roles of limited resection in the management of lung adenocarcinomas measuring 1 cm or less in size. Large prospective randomized studies are necessary to address these issues. In our cohort, we did not study the molecular characterization of the cases, such as EGFR and ALK mutational status. It could be interesting for us to investigate the correlations between tumor heterogeneity and molecular characterization in the future.
In summary, our study of small lung adenocarcinomas in sizes 1 cm or less demonstrates that the2015 WHO classification identifies prognostically significant histological subtypes. Patientys with adenocarcinoma in situ and minimally invasive adenocarcinoma had excellent prognosis. In highly heterogeneous invasive adenocarcinoma, the presence of micropapillary component of 5% or greater was associated with high risk of lymph node metastasis and recurrence. Among patients with stage Ia tumors, limited resection had higher risk of recurrence than did lobectomy.
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